Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Loss of muscle satellite cells during aging has been thought to contribute to sarcopenia, but experimentally induced depletion of these cells in adult mice does not result in this condition.
Development and validation of a genetically encoded system in which gene expression is regulated remotely and noninvasively by either low-frequency radio waves or a static magnetic field.
Georgiou and colleagues describe a single-cell, emulsion-based approach for the high-throughput determination of the paired antibody variable heavy and light chain (VH-VL) repertoire encoded by the more than 2 × 106 B cells in human peripheral blood samples.
A rationally designed peptide agonist that targets three key hormone receptors reduces obesity and its complications in a manner superior to other agonists.
Binding of aged, desialylated platelets to the Ashwell-Morell receptor induces hepatic expression of the cytokine thrombopoietin via JAK2-STAT3 signaling, providing a feedback mechanism to control platelet production.
Our list of newsmakers this year includes a range of nonconformists, from a scientist advocating population-wide genetic tests to a doctor who caused a stir while waiting for takeout food.
Vascular endothelial growth factor A (VEGF-A) is a potent proangiogenic cytokine elevated in patients with peripheral artery disease (PAD). A new study links impaired vascular regrowth in PAD to increased expression of an antiangiogenic splice variant of VEGF-A.
Diffuse intrinsic pontine glioma is a uniformly lethal malignant tumor of infancy with no effective therapies. A new study reveals that inhibition of JMJD3 has robust antitumor activity in diffuse intrinsic pontine glioma xenografts.
At first glance, 2014 may seem like a year dominated by disease outbreaks, from polio's reemergence in parts of Asia to the Ebola epidemic that still continues to make headlines. But a closer look indicates 2014 was replete with regulatory rulings, big investments in genomic medicine and activism in the name of research funding.
This year's newsworthy drugs made major strides against infectious diseases, cancer and more. Some others received attention for controversies they stemmed or stomped. Here is a look at the therapies that leapt forward, some that are in limbo, and others that fell by the wayside.
Frontotemporal dementia (FTD) is a neurodegenerative disease that causes social dysfunction and other symptoms. A new study suggests that social dysfunction in FTD is due to decreased microRNA-124 expression and resulting changes in glutamate receptor composition in the prefrontal cortex.